The acute respiratory distress syndrome commonly accompanies critical illness and is associated with significant morbidity and mortality. The implementation of life saving therapies is dependent on accurately identifying patients with this syndrome; however, beyond clinical definitions, we lack ancillary tests aimed at this specific diagnosis. This commentary discusses recent advances in the use of biomarkers to fill this diagnostic void.